ES548424A0 - Procedimiento para la obtencion de un compuesto de platino para utilizar en quimioterapia del cancer. - Google Patents

Procedimiento para la obtencion de un compuesto de platino para utilizar en quimioterapia del cancer.

Info

Publication number
ES548424A0
ES548424A0 ES548424A ES548424A ES548424A0 ES 548424 A0 ES548424 A0 ES 548424A0 ES 548424 A ES548424 A ES 548424A ES 548424 A ES548424 A ES 548424A ES 548424 A0 ES548424 A0 ES 548424A0
Authority
ES
Spain
Prior art keywords
procedure
obtaining
cancer chemotherapy
platinum compound
platinum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES548424A
Other languages
English (en)
Other versions
ES8801168A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson Matthey PLC
Original Assignee
Johnson Matthey PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB848427767A external-priority patent/GB8427767D0/en
Priority claimed from GB848429030A external-priority patent/GB8429030D0/en
Priority claimed from GB858503432A external-priority patent/GB8503432D0/en
Application filed by Johnson Matthey PLC filed Critical Johnson Matthey PLC
Publication of ES8801168A1 publication Critical patent/ES8801168A1/es
Publication of ES548424A0 publication Critical patent/ES548424A0/es
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086Platinum compounds
    • C07F15/0093Platinum compounds without a metal-carbon linkage
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES548424A 1984-11-02 1985-10-31 Procedimiento para la obtencion de un compuesto de platino para utilizar en quimioterapia del cancer. Expired ES8801168A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB848427767A GB8427767D0 (en) 1984-11-02 1984-11-02 Solubilised platinum compound
GB848429030A GB8429030D0 (en) 1984-11-16 1984-11-16 Solubilised platinum compound
GB858503432A GB8503432D0 (en) 1985-02-11 1985-02-11 Solubilised platinum compound

Publications (2)

Publication Number Publication Date
ES8801168A1 ES8801168A1 (es) 1987-02-16
ES548424A0 true ES548424A0 (es) 1987-02-16

Family

ID=27262501

Family Applications (1)

Application Number Title Priority Date Filing Date
ES548424A Expired ES8801168A1 (es) 1984-11-02 1985-10-31 Procedimiento para la obtencion de un compuesto de platino para utilizar en quimioterapia del cancer.

Country Status (10)

Country Link
US (1) US4696918A (es)
EP (1) EP0181166A3 (es)
KR (1) KR860003830A (es)
AU (1) AU4931985A (es)
DK (1) DK500185A (es)
ES (1) ES8801168A1 (es)
FI (1) FI854301A (es)
GR (1) GR852655B (es)
HU (1) HUT40677A (es)
IL (1) IL76889A0 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0665648B2 (ja) * 1985-09-25 1994-08-24 塩野義製薬株式会社 白金系抗癌物質の安定な凍結真空乾燥製剤
CS269719B1 (en) * 1986-12-29 1990-05-14 Kiss Frantisek Platinum cytostatic
US4956459A (en) * 1987-07-17 1990-09-11 Georgetown University Platinum compounds suitable for use as pharmaceuticals
JPH01146826A (ja) * 1987-12-03 1989-06-08 Nippon Kayaku Co Ltd 白金化合物の凍結乾燥製剤
DE3879453D1 (en) * 1988-01-09 1993-04-22 Asta Medica Ag 1,2-bis(aminomethyl)cyclobutan-platin-komplexe.
US5132385A (en) * 1990-12-14 1992-07-21 General Electric Company One part heat curable organopolysiloxane compositions
US5300280A (en) * 1992-02-14 1994-04-05 Mallinckrodt Medical, Inc. Stabilized radiopharmaceutical kits
KR100351707B1 (ko) * 1994-12-30 2002-11-02 에스케이케미칼주식회사 플라티늄(II)착화합물과히드록시프로필β-사이클로덱스트린의복합체
CN1121380C (zh) 2000-03-03 2003-09-17 北京兴大豪斯科技有限公司 一种抗肿瘤的双二羧酸二氨络铂衍生物及其药物组合物
AUPQ641100A0 (en) * 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
WO2005102312A1 (en) * 2004-04-27 2005-11-03 Mayne Pharma Limited Concentrated oxaliplatin solutions
CZ2004964A3 (cs) * 2004-09-14 2006-03-15 Pliva-Lachema A. S. Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
DE102005047308A1 (de) * 2005-09-30 2007-04-05 Martin-Luther-Universität Halle-Wittenberg Platin(II)Verbindungen aus 2-substituierten Propan-1,3-diaminen zur Verwendung als Chemotherapeutikum
US20070123478A1 (en) * 2005-11-28 2007-05-31 Rowe Vernon D Compositions useful for reducing nephrotoxicity and methods of use thereof
US7658913B2 (en) 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
CZ300120B6 (cs) * 2006-06-20 2009-02-11 Pliva - Lachema A. S. Farmaceutická kompozice pro injekcní podání
FR2989001B1 (fr) * 2012-04-06 2017-07-21 Centre Nat Rech Scient Microparticules et nanoparticules constituees de polysaccharides hydrophobises et d'une alpha-cyclodextrine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2959580A (en) * 1956-10-17 1960-11-08 Univ Minnesota Formation of inclusion compounds
GB978485A (en) * 1960-10-26 1964-12-23 Astra Apotekarnes Kem Fab Iron preparations for intramuscular injection
US3821192A (en) * 1971-08-18 1974-06-28 Central Pharmacal Co Process for preparing an iron-saccharide complex
CH588505A5 (es) * 1972-06-08 1977-06-15 Research Corp
DE2260536C3 (de) * 1972-12-11 1975-07-10 Fa. H. Trommsdorff, 5100 Aachen MolekiileinschluBverbindungen aus einem Silberalkanolammin-Komplex und beta-Cycloheptaamylose, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4180567A (en) * 1977-09-02 1979-12-25 Pharmachem Corporation Iron preparations and methods of making and administering the same
US4234499A (en) * 1979-03-07 1980-11-18 Engelhard Minerals & Chemicals Corporation Cis-diammireplatinum(II) organophosphate complexes
JPS57123198A (en) * 1981-01-23 1982-07-31 Shionogi & Co Ltd Novel platinum complex
HU183430B (en) * 1981-05-12 1984-05-28 Chinoin Gyogyszer Es Vegyeszet Process for producing cyclodextrine inclusion complexes of n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine or n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine-hydrochloride
JPS5921697A (ja) * 1982-06-24 1984-02-03 Yoshinori Kitani 新規な白金錯体
US4500465A (en) * 1982-06-28 1985-02-19 Engelhard Corporation Solubilized platinum (II) complexes
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4584392A (en) * 1982-11-10 1986-04-22 Inco Alloys International, Inc. Platinum and palladium complexes
US4565884A (en) * 1983-05-10 1986-01-21 Andrulis Research Corporation Bis-platinum complexes as antitumor agents
US4587331A (en) * 1984-12-17 1986-05-06 American Cyanamid Company Platinum complexes of polyhydroxylated alkylamines and 2-polyhydroxylated alkyl-1,2-diaminoethanes

Also Published As

Publication number Publication date
EP0181166A3 (en) 1987-07-29
ES8801168A1 (es) 1987-02-16
HUT40677A (en) 1987-01-28
IL76889A0 (en) 1986-02-28
GR852655B (es) 1986-02-26
FI854301A0 (fi) 1985-11-01
KR860003830A (ko) 1986-06-13
DK500185D0 (da) 1985-10-31
AU4931985A (en) 1986-05-08
US4696918A (en) 1987-09-29
DK500185A (da) 1986-05-03
FI854301A (fi) 1986-05-02
EP0181166A2 (en) 1986-05-14

Similar Documents

Publication Publication Date Title
ES540597A0 (es) Procedimiento para la obtencion de piridonas.
FI855035A (fi) Vaermehaerdbara silikonkompositioner, anvaendning daerav och stabiliseringsmedel foer anvaendning daeri.
FI853626A0 (fi) Isoxazolkarboxylsyraderivat, deras framstaellning och anvaendning.
FI852916L (fi) Kinonderivat, deras framstaellning och anvaendning.
ES548424A0 (es) Procedimiento para la obtencion de un compuesto de platino para utilizar en quimioterapia del cancer.
ES507474A0 (es) Procedimiento para preparar complejos de platino (iv)-diami-na.
FI851824L (fi) Lampor foer flygstationers upphoejda startbanor, taxibanor och troeskelkanter.
ES514391A0 (es) Procedimiento para la produccion de ranuras en un filamento alargado.
IT8519727A0 (it) Complessi del platino (iv)antineoplastici.
DE3587185D1 (de) Annaeherungsdetektor.
FI853698L (fi) Pyrimidinderivat, foerfarande foer deras framstaellning och deras blandningar.
DE3580904D1 (de) Notrutsche.
ES544918A0 (es) Celula para dialisis.
FI850266L (fi) Azolylarylalkanolderivat, foerfarande foer deras framstaellning och deras anvaendning.
FI852657L (fi) Heterocykliska farmaceutiska foereningar, framstaellning och anvaendning.
FI854535A0 (fi) Flavolignanderivat, foerfarande foer deras framstaellning och dessa foereningar innehaollande laekemedel.
FI853623A0 (fi) Fosforsyravinylbenzylestrar, deras framstaellning och anvaendning.
FI853062A0 (fi) Haollbara, vaesentligen fuktfria tuggummikompositioner och foerfarande foer deras framstaellning.
FI855131A0 (fi) 8 -acylaminoergoliner, deras framstaellning och farmaceutiska sammansaettningar innehaollande desamma.
FI852676L (fi) Substituerade guanidinobenzoesyrafenylestrar, foerfarande foer deras framstaellning och deras anvaendning saosom laekemedel.
FI850324L (fi) Benzopyranderivat, dessa innehaollande kompositioner och foerfarande foer deras framstaellning.
FI852105A0 (fi) Acylerade sockerderivat, foerfarande foer deras framstaellning och deras anvaendning.
ES549429A0 (es) Procedimiento para la obtencion de acemetacina.
FI850702A0 (fi) Diazepinindoler, deras framstaellning och dessa innehaollande farmaceutiska foereningar.
FI851154L (fi) Kondenserade sjulemmande ringfoereningar, deras framstaellning och anvaendning.